// App-Quantinova.ai

P283 : Bowel urgency in patients with moderate to severe ulcerative colitis: prevalence and correlation with clinical outcomes, biomarker levels, and health-related quality of life from U-ACHIEVE, a Phase 2b study of upadacitinib

Researchers

Presenter

  • S Ghosh

Principal Investigators

  • E Louis

  • E V Loftus Jr

  • W Reinisch

  • F Cataldi

  • W Zhou

  • W-J Lee

  • J Panes

Medical Centers

  • University of Birmingham, Institute of Immunology and Immunotherapy, NIHR Biomedical Research Centre, Institute of Translational Medicine, Birmingham, UK

  • University of Liege, Liege, Belgium.

  • Mayo Clinic College of Medicine, Rochester, MN

  • Medical University of Vienna, Vienna, Austria

  • AbbVie, Inc., North Chicago, IL

  • University of Barcelona, Hospital Clinic Barcelona, Barcelona, Spain

Locations

  • United Kingdom

  • Belgium

  • United States

  • Austria

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

  • Autoimmune (AI)

  • Genetic Disorder

  • Gastroenterology (GU)

Disease

  • Inflammatory bowel disease

  • Ulcerative colitis

Biomarkers

  • N/A

Drug/Treatment

  • ABT-494

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • II

Study Id's

  • NCT02819635

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved